Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review-Reference-Cited by-同舟云学术

Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review

Published:2021-09-21 Issue:3 Volume:30 Page:2839-2851
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Maloney Nolan J.,Rana Jasmine,Yang Jason J.,Zaba Lisa C.,Kwong Bernice Y.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-021-06543-9.pdf

Reference42 articles.

1. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39

2. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R et al (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8):871–878

3. Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C et al (2019) Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw : JNCCN 17(4):367–402

4. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL et al (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480–1492

5. Russo I, Zorzetto L, Chiarion Sileni V, Alaibac M (2018) Cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma. Scientifica 2018(30):5036213

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Arzneimittelexantheme unter Immun- und zielgerichteter onkologischer Therapie;Die Dermatologie;2024-05-21

2. Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part II. Diagnosis and Management.;Journal of the American Academy of Dermatology;2023-07

3. Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part I. Epidemiology, Pathogenesis, Clinicopathological Features, and Prognosis.;Journal of the American Academy of Dermatology;2023-07

4. Severe drug eruption after antibiotic administration in patients receiving immune checkpoint inhibitors: A monocentric case series;JEADV Clinical Practice;2023-02-27